2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P9930
    Evolocumab 1256937-27-5
    Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation.
    Evolocumab
  • HY-14832
    Ataluren 775304-57-9 ≥98.0%
    Ataluren (PTC124) is an orally available CFTR-G542X nonsense allele inhibitor.
    Ataluren
  • HY-P99930
    Efruxifermin 2375240-92-7 98.32%
    Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis.
    Efruxifermin
  • HY-15253
    Tiplaxtinin 393105-53-8 99.03%
    Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 μM.
    Tiplaxtinin
  • HY-113046
    5-Methyltetrahydrofolic acid 134-35-0 99.77%
    5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases.
    5-Methyltetrahydrofolic acid
  • HY-W011183
    4-Nitrophenyl-N-acetyl-β-D-glucosaminide 3459-18-5
    4-Nitrophenyl-N-acetyl-β-D-glucosaminide, an artificial substrate of N-acetyl-beta-D-hexosaminidase (NAGase), can be used in rapid and accurate rate assay for N-acetyl-beta-D-hexosaminidase. 4-Nitrophenyl-N-acetyl-β-D-glucosaminide is highly soluble and stable. 4-Nitrophenyl-N-acetyl-β-D-glucosaminide can be used for the study of renal tubular injury.
    4-Nitrophenyl-N-acetyl-β-D-glucosaminide
  • HY-N0830S6
    Palmitic acid-13C16 56599-85-0 ≥99.0%
    Palmitic acid-13C16 is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-13C16
  • HY-10284
    Linagliptin 668270-12-0 ≥98.0%
    Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
    Linagliptin
  • HY-17468
    Bumetanide 28395-03-1 99.95%
    Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
    Bumetanide
  • HY-B0135
    Furosemide 54-31-9 99.83%
    Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.
    Furosemide
  • HY-138620
    MCU-i4 371924-24-2 99.87%
    MCU-i4 blocks the IP3-dependent mitochondrial Ca2+-uptake, maintaining the gatekeeping role of their target.
    MCU-i4
  • HY-19708
    KIRA6 1589527-65-0 99.86%
    KIRA6 is an advanced small-molecule IRE1α RNase kinase inhibitor with an IC50 of 0.6 µM. KIRA6 can trigger an apoptotic response.
    KIRA6
  • HY-A0124A
    Sapropterin dihydrochloride 69056-38-8 ≥98.0%
    Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin also drives autoimmunity. Sapropterin can be used in study of phenylketonuria (PKU).
    Sapropterin dihydrochloride
  • HY-14415
    SR8278 1254944-66-5 ≥98.0%
    SR8278 is a REV-ERBα antagonist and inhibits the REV-ERBα transcriptional repression activity with an EC50 of 0.47 μM. SR8278 is used to regulate the metabolism in organisms and study biological rhythm. SR8278 also can be used for the research of Duchenne muscular dystrophy and Alzheimer's disease.
    SR8278
  • HY-A0005
    Clofarabine 123318-82-1 99.88%
    Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit.
    Clofarabine
  • HY-145597
    KL-11743 1369452-53-8 99.40%
    KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC50s of 115, 137, 90, and 68 nM for GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors to induce cell death. In addition, KL-11743 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis.
    KL-11743
  • HY-W018392
    Mono-(2-ethylhexyl) phthalate 4376-20-9
    Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD).
    Mono-(2-ethylhexyl) phthalate
  • HY-CP001
    D-Trehalose, Carrier Protein 99-20-7 99.76%
    D-Trehalose is a disaccharide formed by a 1,1-glycosidic bond between two α-glucose units and is widely used as a food ingredient and pharmaceutical excipient. D-Trehalose is known to protect and stabilise proteins. For long-term storage, recombinant protein solution should be diluted further with 5% D-Trehalose, Carrier Protein.
    D-Trehalose, Carrier Protein
  • HY-W015883
    Fumaric acid 110-17-8 ≥98.0%
    Fumaric acid is an unsaturated dicarbonic acid, an intermediate product of the citric acid cycle that provides intracellular energy in the form of ATP. Fumaric acid exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway dependent on p38 MAPK. Fumaric acid can be used in the study of pregnancy-induced hypertension.
    Fumaric acid
  • HY-16737
    Elafibranor 923978-27-2 99.66%
    Elafibranor (GFT505) is a PPARα/δ agonist with EC50s of 45 and 175 nM, respectively. Elafibranor can be used for the study of primary biliary cholangitis.
    Elafibranor
Cat. No. Product Name / Synonyms Application Reactivity